Market Research Reports, Inc. Ophthalmology Therapeutics Market to Reach $3.3 Billion in 2019, New Report

The ophthalmology therapeutics market for Dry Eye Syndrome (DES) and glaucoma in four Asia-Pacific (APAC) countries — India, Australia, China and Japan — will increase from $2.4 billion in 2012 to $3.3 billion in 2019, at a Compound Annual Growth Rate (CAGR) of 5%.


Lewes, DE -- (SBWIRE) -- 11/27/2013 -- The latest report "Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity" states that the Indian market is expected to show the fastest growth over the forecast period, with almost a double-digit CAGR of 9.9%, followed by China with a CAGR of 5%.

In 2012, Japan had the largest share of the ophthalmology market with a share of $1,065m (45%), followed by China, India and Australia with shares of $767m (33%), $427m (18%) and $95m (4%), respectively.

According to the leading author of this report: “Some of the major factors driving the market is the growing awareness of the importance of detecting ophthalmic diseases early, the availability of effective diagnostic tools, and an increase in the prevalence of both DES and glaucoma.”

Currently, there are five molecules in the Pre-registration stage of development that are expected to be granted approval within the forecast period. Two of these are indicted for DES and three for glaucoma.

Nearly 36% of the pipeline for glaucoma and DES are molecules in the late stages of development (Phases II and III), and of these, 21 molecules are indicated for DES and 28 are for glaucoma.

Author also says: “The drug approval processes in many APAC countries, including Japan and China, require clinical trials to be run domestically in order to account for differences in drug metabolism between populations of different ethnicities. This can delay new drug launches, but in the long term it secures greater confidence in safety and efficacy profiles.”

However, many ophthalmic medications, such as Lumigan, are expected to lose patent exclusivity during the forecast period. Report therefore expects the resulting increase in generic drug use to act as a barrier to the future growth of the ophthalmology therapeutics market.

This report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES) in Asia-Pacific (APAC) markets of India, China, Japan and Australia. It also provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

Inquire about this report:

Browse more Healthcare Market Research Reports
For graphical representation of the reports subscribe us on YouTube at: